viewECSC Group PLC

ECSC Group lands two major cybersecurity contracts

The new work has been won through the Managed Detection and Response Division

ECSC Group PLC -

ECSC Group PLC (LON:ECSC), the cybersecurity services specialist, has landed two major contracts with a combined revenue value of £580,000.

The new work has been won through the Managed Detection and Response (MDR) Division and the unnamed customers are major companies in the rail and building supplies sectors.

The company said it will provide around-the-clock cybersecurity monitoring, detection and response support in the UK and Australia employing its Kepler Artificial Intelligence technology.

"These new contracts demonstrate the resilience of the long-established MDR service that has continued to grow throughout 2020 in line with our strategy to expand MDR recurring revenue as a proportion of overall revenue,” ECSC chief executive, Ian Mann said in a statement.

Separately, ECSC said it has delivered its first Nebula Cloud MDR service to another new client, utilising its AI technologies. 

The company's MDR services allow clients to receive immediate alerts flagging potential incidents, and combine expert advice, incident response and containment, preventing escalation to costly breaches.

"Following the introduction of the 2019 GDPR-related fines from the Information Commissioner's Office, it is increasingly critical for all organisations to have effective cybersecurity breach detection and expert response," explained CEO Mann.

Quick facts: ECSC Group PLC


Price: 90.5 GBX

Market Cap: £9.06 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


CBD Science looks to raise £2M in Series A to advance its plant-based...

CBD Science Group PLC CEO Dr Michael Raymont joined Proactive New York to discuss the London, England-based group's Series A funding round, on the Crowd for Angels platform. Raymont says the privately-held company, which is developing plant-based cannabinoid pharmaceutical therapeutics to...

11 hours, 41 minutes ago

2 min read